DE69535282D1 - Verwendung von bakteriellen enzymen z.b. heparinasen, chodroitinasen um wundheilungprozesse zu modulieren - Google Patents

Verwendung von bakteriellen enzymen z.b. heparinasen, chodroitinasen um wundheilungprozesse zu modulieren

Info

Publication number
DE69535282D1
DE69535282D1 DE69535282T DE69535282T DE69535282D1 DE 69535282 D1 DE69535282 D1 DE 69535282D1 DE 69535282 T DE69535282 T DE 69535282T DE 69535282 T DE69535282 T DE 69535282T DE 69535282 D1 DE69535282 D1 DE 69535282D1
Authority
DE
Germany
Prior art keywords
cell
heparinases
extracellular matrix
growth factors
heparan sulfate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69535282T
Other languages
English (en)
Other versions
DE69535282T2 (de
Inventor
Joseph Zimmermann
Israel Vlodavsky
Clark Bennett
Pamela Danagher
Richard Broughton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biomarin Pharmaceutical Inc
Original Assignee
Biomarin Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomarin Pharmaceutical Inc filed Critical Biomarin Pharmaceutical Inc
Publication of DE69535282D1 publication Critical patent/DE69535282D1/de
Application granted granted Critical
Publication of DE69535282T2 publication Critical patent/DE69535282T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria
DE69535282T 1994-07-08 1995-07-07 Verwendung von bakteriellen enzymen z.b. heparinasen, chodroitinasen um wundheilungprozesse zu modulieren Expired - Fee Related DE69535282T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US273109 1994-07-08
US08/273,109 US5997863A (en) 1994-07-08 1994-07-08 Attenuation of wound healing processes
PCT/US1995/008608 WO1996001648A1 (en) 1994-07-08 1995-07-07 Attenuation of wound healing processes

Publications (2)

Publication Number Publication Date
DE69535282D1 true DE69535282D1 (de) 2006-12-14
DE69535282T2 DE69535282T2 (de) 2007-05-24

Family

ID=23042598

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69535282T Expired - Fee Related DE69535282T2 (de) 1994-07-08 1995-07-07 Verwendung von bakteriellen enzymen z.b. heparinasen, chodroitinasen um wundheilungprozesse zu modulieren

Country Status (9)

Country Link
US (1) US5997863A (de)
EP (1) EP0769961B1 (de)
JP (1) JP4152433B2 (de)
AT (1) ATE344051T1 (de)
AU (1) AU707007B2 (de)
CA (1) CA2194370C (de)
DE (1) DE69535282T2 (de)
ES (1) ES2279514T3 (de)
WO (1) WO1996001648A1 (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0852491B1 (de) * 1995-09-29 2004-08-11 BioMarin Pharmaceutical Inc Verwendung von heparinasen zur verminderung von entzündungsreaktionen
US6217863B1 (en) 1995-10-30 2001-04-17 Massachusetts Institute Of Technology Rationally designed polysaccharide lyases derived from heparinase I
GB2317182B (en) * 1996-09-11 2000-11-01 Johnson & Johnson Medical Sulfated polysaccharides and uses thereof in medical treatment
US20040213789A1 (en) * 1997-09-02 2004-10-28 Oron Yacoby-Zeevi Heparanase activity neutralizing anti-heparanase monoclonal antibody and other anti-heparanase antibodies
US6177545B1 (en) * 1997-09-02 2001-01-23 Insight Strategy & Marketing Ltd. Heparanase specific molecular probes and their use in research and medical applications
US20020088019A1 (en) * 1997-09-02 2002-07-04 Oron Yacoby-Zeevi Methods of and pharmaceutical compositions for improving implantation of embryos
US6699672B1 (en) * 1997-09-02 2004-03-02 Insight Biopharmaceuticals Ltd. Heparanase specific molecular probes and their use research and medical applications
US20010006630A1 (en) * 1997-09-02 2001-07-05 Oron Yacoby-Zeevi Introducing a biological material into a patient
US20030161823A1 (en) * 1998-08-31 2003-08-28 Neta Ilan Therapeutic and cosmetic uses of heparanases
WO1999046368A2 (en) * 1998-03-13 1999-09-16 Biomarin Pharmaceuticals Carbohydrate-modifying enzymes for burn and wound debridement and methods for treatment
US7056504B1 (en) 1998-08-27 2006-06-06 Massachusetts Institute Of Technology Rationally designed heparinases derived from heparinase I and II
WO2000012726A2 (en) 1998-08-27 2000-03-09 Massachusetts Institute Of Technology Rationally designed heparinases derived from heparinase i and ii
US20030217375A1 (en) * 1998-08-31 2003-11-20 Eyal Zcharia Transgenic animals expressing heparanase and uses thereof
WO2000052178A1 (en) * 1999-03-01 2000-09-08 Insight Strategy & Marketing Ltd. Polynucleotide encoding a polypeptide having heparanase activity and expression of same in genetically modified cells
EP1190364A2 (de) * 1999-04-23 2002-03-27 Massachusetts Institute Of Technology Verfahren und system für die notation von polymeren
US6979563B1 (en) 1999-11-17 2005-12-27 Biomarin Enzymes, Inc. Attenuation of tumor growth, metastasis and angiogenesis
ATE413886T1 (de) * 1999-11-17 2008-11-15 Biomarin Pharm Inc Verminderung von angiogenese unter verwendung chondroitinsulfat abbauender enzyme
WO2001038399A1 (fr) * 1999-11-24 2001-05-31 Seikagaku Corporation Procede de traitement des maladies des tissus superficiels
EP1266013B1 (de) 2000-03-08 2014-10-15 Massachusetts Institute Of Technology Heparinase iii und deren verwendungen
WO2002023190A2 (en) 2000-09-12 2002-03-21 Massachusetts Institute Of Technology Methods and products related to low molecular weight heparin
CA2423469A1 (en) 2000-10-18 2002-04-25 Massachusetts Institute Of Technology Methods and products related to pulmonary delivery of polysaccharides
WO2002091999A2 (en) * 2001-05-09 2002-11-21 Geron Corporation Treatment for wounds
US6972168B2 (en) * 2001-08-13 2005-12-06 University Of Florida Research Foundation, Incorporated Materials and methods for nerve grafting, selection of nerve grafts, and in vitro nerve tissue culture
US6671189B2 (en) * 2001-11-09 2003-12-30 Minebea Co., Ltd. Power converter having primary and secondary side switches
GB0205022D0 (en) 2002-03-04 2002-04-17 Univ Cambridge Tech Materials and methods for the treatment of cns damage
US6974592B2 (en) * 2002-04-11 2005-12-13 Ocean Nutrition Canada Limited Encapsulated agglomeration of microcapsules and method for the preparation thereof
EP1575548B1 (de) 2002-05-04 2011-03-09 Acorda Therapeutics, Inc. Zusammensetzungen und verfahren zur förderung des neuronalen wachstums
US6962699B2 (en) 2002-06-03 2005-11-08 Massachusetts Institute Of Technology Rationally designed polysaccharide lyases derived from chondroitinase B
AU2003265561A1 (en) * 2002-08-15 2004-03-03 Acorda Therapeutics, Inc. Chimeric protein
ES2347045T3 (es) * 2002-11-04 2010-10-25 Ocean Nutrition Canada Limited Microcapsulas que tienen multiples cortezas, y metodo para su preparacion.
US7959914B2 (en) * 2003-05-16 2011-06-14 Acorda Therapeutics, Inc. Methods of reducing extravasation of inflammatory cells
MXPA05012305A (es) * 2003-05-16 2006-04-18 Acorda Therapeutics Inc Composiciones y metodos para el tratamiento de lesiones del snc.
MXPA05012307A (es) 2003-05-16 2006-07-03 Acorda Therapeutics Inc Mutantes que degradan proteoglicanos para tratamiento del snc.
US20060269552A1 (en) * 2003-06-09 2006-11-30 Oron Yacoby-Zeevi Heparanase activity neutralizing anti-heparanase monclonal antibody and other anti-heparanase antibodies
US7772185B2 (en) * 2004-01-30 2010-08-10 Emory University Method for promoting axonal outgrowth in damaged nerves
WO2005087920A2 (en) 2004-03-10 2005-09-22 Massachusetts Institute Of Technology Recombinant chondroitinase abc i and uses thereof
AU2005244933B2 (en) * 2004-05-18 2011-08-04 Acorda Therapeutics, Inc. Methods of purifying chondroitinase and stable formulations thereof
US8034450B2 (en) * 2005-01-21 2011-10-11 Ocean Nutrition Canada Limited Microcapsules and emulsions containing low bloom gelatin and methods of making and using thereof
US9968120B2 (en) * 2006-05-17 2018-05-15 Dsm Nutritional Products Ag Homogenized formulations containing microcapsules and methods of making and using thereof
EP1928490B8 (de) 2005-09-26 2012-10-03 Acorda Therapeutics, Inc. Zusammensetzungen und verfahren zur verwendung von chondroitinase-abci-mutanten
WO2007049361A1 (ja) * 2005-10-27 2007-05-03 Stelic Corp. 肝線維化抑制剤
US7767420B2 (en) * 2005-11-03 2010-08-03 Momenta Pharmaceuticals, Inc. Heparan sulfate glycosaminoglycan lyase and uses thereof
US7691612B2 (en) * 2005-11-03 2010-04-06 Momenta Pharmaceuticals, Inc. Heparan sulfate glycosaminoglycan lyase and uses thereof
US7691613B2 (en) * 2006-11-03 2010-04-06 Momenta Pharmaceuticals, Inc. Glycosaminoglycan lyase IV and uses thereof
KR20090029699A (ko) * 2006-04-07 2009-03-23 오션 뉴트리션 캐나다 리미티드 낮은 계면장력 물질을 가지는 에멀젼 및 마이크로캡슐, 제조방법 및 이용방법
NZ573327A (en) * 2006-06-05 2012-07-27 Ocean Nutrition Canada Ltd Microcapsules with improved shells
US7722864B2 (en) 2006-10-10 2010-05-25 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase ABCI mutants
WO2008085997A2 (en) 2007-01-10 2008-07-17 Ocean Nutrition Canada, Ltd. Vegetarian microcapsules
US20090286289A1 (en) * 2008-03-10 2009-11-19 Pang Danny Z Production of Hyaluronate Unsaturated Disaccharides and its Application
EP2756849B1 (de) * 2011-09-15 2016-03-16 Seikagaku Corporation Skelettmuskelregenerationsförderer
US9238090B1 (en) 2014-12-24 2016-01-19 Fettech, Llc Tissue-based compositions
CN109182321A (zh) * 2018-09-14 2019-01-11 深圳市长征生物科技有限公司 肝素黄杆菌肝素酶ⅰ的高效制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4760131A (en) * 1986-04-23 1988-07-26 Collagen Corporation Wound-healing composition
US5169772A (en) * 1988-06-06 1992-12-08 Massachusetts Institute Of Technology Large scale method for purification of high purity heparinase from flavobacterium heparinum
JPH04503734A (ja) * 1988-12-01 1992-07-02 ボック、エドワード 脈動、浮遊状態で搬送、処理する改良された装置
US5116615A (en) * 1989-01-27 1992-05-26 Immunolytics, Inc. Method for treating benign prostatic hypertrophy
KR927003090A (ko) * 1989-08-23 1992-12-17 하다사 메디칼 오르가니제이션 헤파린효소를 포함하는 상처 치유 약제
US5242810A (en) * 1990-12-07 1993-09-07 Biogen, Inc. Bifunctional inhibitors of thrombin and platelet activation
US5262325A (en) * 1991-04-04 1993-11-16 Ibex Technologies, Inc. Method for the enzymatic neutralization of heparin
US5389539A (en) * 1992-11-30 1995-02-14 Massachusetts Institute Of Technology Purification of heparinase I, II, and III from Flavobacterium heparinum
WO1995013091A1 (en) * 1993-11-12 1995-05-18 International Technology Management Associates, Ltd. Methods of repairing connective tissues
CA2176934A1 (en) * 1993-11-17 1995-05-26 Ramnath Sasisekharan Method for inhibiting angiogenesis using heparinase

Also Published As

Publication number Publication date
WO1996001648A1 (en) 1996-01-25
JPH10506609A (ja) 1998-06-30
US5997863A (en) 1999-12-07
EP0769961B1 (de) 2006-11-02
EP0769961A1 (de) 1997-05-02
DE69535282T2 (de) 2007-05-24
JP4152433B2 (ja) 2008-09-17
AU707007B2 (en) 1999-07-01
ES2279514T3 (es) 2007-08-16
AU3094995A (en) 1996-02-09
CA2194370C (en) 2001-02-27
ATE344051T1 (de) 2006-11-15
CA2194370A1 (en) 1996-01-25

Similar Documents

Publication Publication Date Title
DE69535282D1 (de) Verwendung von bakteriellen enzymen z.b. heparinasen, chodroitinasen um wundheilungprozesse zu modulieren
US7056711B2 (en) Attenuation of fibroblast proliferation
DE69636410D1 (de) Mutierte alpha-amylase
IL157644A0 (en) Method for the purification of a protein preparation with erythropoietin activity
FI841358A (fi) Biologiskt aktiv sammansaettning foer rening av avfallsvatten och avluft.
MX9806064A (es) Composicion de enzimas para disociacion de tejidos.
US8785606B2 (en) Compositions and methods for promoting neuronal outgrowth
ATE310098T1 (de) Dna kodierend für glutaminsäure-gesteuerte chloridkanäle
AU7042196A (en) Method for controlling the suppression of the neoplastic phenotype
DE69724798D1 (de) Mannose-6-phosphat enthaltendes mittel und dessen verwendung bei der behandlungfibrotischer erkrankungen
WO2000006713A8 (en) Methods for recombinant protein production in mammalian cells comprising co-expression with fetuin
DE60040800D1 (de) Verminderung von angiogenese unter verwendung chondroitinsulfat abbauender enzyme
DK0858502T3 (da) Normale, neurale epitelprecursorceller
EP0330218A3 (de) Lysyl-Oxidase-Inhibitoren
IL145646A0 (en) Production of pancreatic procarboxy-peptidase b, isoforms and muteins thereof, and their use
Funderburgh et al. Corneal glycosaminoglycan synthesis in long-term organ culture.
FI963755A (fi) Glutamaatti-dekarboksylaasi-aktiivisuutta (GAD-aktiivisuutta) koodaavat yhdistelmä-DNA-tekniset virukset
AU4367600A (en) Dsp-3 dual-specificity phosphatase
AU1598297A (en) Method of inactivation of ras subfamily proteins and agents therefor
EP1839671A2 (de) Abschwächung der Fibroplastprofileration
Blinova et al. Effects of fibroblasts, collagen, and laminin on healing of superficial split wounds
IT1284658B1 (it) Stimolatore dell'attivita' enzimatica in cellule batteriche
EP0952220A3 (de) Verfahren zur Voraussage aktiven Zuwachses von Bakterien, die einer Oberfläche anhaften

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee